Is Gonadal Therapy a Promoter of Breast Cancer? Incidence of Breast Cancer in a Cohort of Survivors of Oncological Diseases Treated with Gonadal Steroids
Open Access
- 1 January 2020
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 13 (1), 347-357
- https://doi.org/10.1159/000506395
Abstract
There is a great controversy about hormonal replacement therapy in women among the members of the scientific community. Cancer survivors have sometimes had their ovary function totally or partially destroyed, thus affecting their development and quality of life. In this study, we were looking for adverse effects caused, eventually, by estroprogestative therapy in a cohort of supplemented survivors. The occurrence of breast cancer was our main concern. Ours is a retrospective study based on the clinical records of 174 survivors of several cancer diseases. Their median ages within each of the following time frames were: diagnosis - 22 years old; start of endocrine treatment - 26 years old, and duration of treatment - 12 years old. Evaluation was composed of breast cancer assessment, osteopenia and osteoporosis incidence, and vascular events. We have found a very low incidence of breast cancer as well as of vascular events. After treatment, a high percentage of our sample displayed bone mass improvement.Keywords
This publication has 30 references indexed in Scilit:
- Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog)Brain Research, 2013
- Effects of hypogonadism on bone metabolism in female adolescents and young adultsNature Reviews Endocrinology, 2012
- Hip fracture in postmenopausal women after cessation of hormone therapyMenopause, 2011
- Breast cancer incidence and hormone replacement therapy: Results from the MISSION study, prospective phaseGynecological Endocrinology, 2007
- Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study GroupJournal of Clinical Oncology, 2005
- Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-reviewHuman Reproduction, 2005
- Use of hormonal replacement therapy after treatment of breast cancerInternational Journal of Gynecology & Obstetrics, 2005
- Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older WomenThe Cache County StudyJAMA, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Malignant Neoplasms in Long-Term Survivors of Bone Marrow TransplantationAnnals of Internal Medicine, 1999